Nautilus Biotechnology
NASDAQ: NAUTSeattle, US · Founded 2020 · Delaware corporation · 151 employees on LinkedIn · 4 known investors
Nautilus develops proteomics technology to unlock the complexity of the human proteome for biomedical research and diagnostics. The company targets pharmaceutical, biotechnology, academic, clinical, and government sectors with advanced protein quantification and analysis platforms.
Founders & leadership
Nautilus Biotechnology was founded in 2020 by Sujal Patel and Parag Mallick.
SP
PM
Parag MallickinFounder & Chief ScientistTrained as an engineer and biochemist, Parag Mallick leads a Stanford research lab working on proteomics, computational and experimental systems biology, artificial intelligence, cancer biology, and nanotechnology, with a focus on disease mechanisms, biomarker discovery, and personalized medicine. He is co-founder and Chief Scientist of Nautilus Biotechnology, which develops a single-molecule protein analysis platform, and advises other biotechnology and diagnostics companies.
ME
Melissa EpperlyinExecutive
NN
Nicholas NelsonExecutive
SS
Subra SankarinSVP Product Development
MM
Matthew MurphyinGeneral Counsel
AM
Anna MowryinCFO
Board
MA
Michael AltmanBoard director
VP
Vijay Pandein𝕏Member Board Of Directors2018–2025General Partner, Andreessen Horowitz at Propagator Ventures
MS
FN
Farzad NazeminBoard Member
MP
Matthew PosardBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$200M disclosed across 1 round · 2021
▶$200MraisedJun 2021 · 38 investors · OtherRule 506(b)
▶$200MraisedJun 2021 · 38 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Melissa EpperlyDirector
- Nicholas NelsonExecutive Officer
- Subra SankarExecutive Officer
- Farzad NazemDirector
- Matthew MurphyExecutive Officer
- Sujal PatelExecutive Officer, Director
- Michael AltmanDirector
- Vijay PandeDirector
- Matthew PosardDirector
- Anna MowryExecutive Officer
- Matthew S. McIlwainDirector
- Parag MallickExecutive Officer, Director
- Offering amount
- $200M
- Amount sold
- $200M
- Sales commissions
- $2M
- Placement agents
- Goldman Sachs & Co. LLC, Jefferies LLC
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBYJU'S236 shared keywordsBYJU'S offers online learning programs, video lessons, and a personalized learning app for students in India, including tutoring and exam-preparation programs for competitive tests such as JEE and NEET.
Bionity216 shared keywordsBionity.com is a German-language B2B trade portal for the life sciences, biotechnology, and pharmaceutical industries, offering news, trends, supplier directories, job listings, and lab and production solutions. Operated by LUMITOS AG, it serves professionals in industry, research, and science and provides online marketing services to reach this B2B audience.
Companies competing with Nautilus Biotechnology for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Nautilus Biotechnology do?
- Nautilus develops proteomics technology to unlock the complexity of the human proteome for biomedical research and diagnostics. The company targets pharmaceutical, biotechnology, academic, clinical, and government sectors with advanced protein quantification and analysis platforms.
- Who founded Nautilus Biotechnology?
- Nautilus Biotechnology was founded by Sujal Patel, Parag Mallick in 2020.
- Who are Nautilus Biotechnology's investors?
- Nautilus Biotechnology's investors include Andreessen Horowitz, Defy Partners, Madrona Venture Group, AME Cloud Ventures.
- How much funding has Nautilus Biotechnology raised?
- Nautilus Biotechnology has disclosed $200M raised across 1 round.
- Where is Nautilus Biotechnology headquartered?
- Nautilus Biotechnology is headquartered in Seattle, US.